MarketPulse

IND filing

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Prelude Therapeutics' KAT6A Degrader Shows Complete Tumor Regressions in Breast Cancer Models

Prelude Therapeutics shows complete tumor regressions with PRT13722, a first-in-class oral KAT6A degrader, planning IND filing mid-2026 and clinical trials by year-end.
PRLDprecision oncologyHR+/HER2- breast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest Advances CAR-T Program With Manufacturing Deal Ahead of 2026 FDA Filing

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.
TPSTclinical trialmultiple myeloma